[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-423158-105":59,"doc-detail-423158-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","plasma-neurodegeneration-and-ad-biomarkers-identify-populations-with-rapid-cognitive-decline","Plasma Neurodegeneration and AD Biomarkers Identify Populations With Rapid Cognitive Decline","","The study develops and validates a risk score for rapid global cognitive decline using neurodegeneration and Alzheimer’s disease (AD) biomarkers measured in frozen plasma from the ARIC cohort. Four biomarkers, amyloid-β ratios, p-tau 181, NFL, and GFAP, are standardized and used to model decline rates. The ARIC-derived risk scores are applied to the ACHIEVE clinical trial for validation, where the top risk quintile shows substantially faster progression. Adding age and MMSE does not improve performance.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasma-neurodegeneration-and-ad-biomarkers-identify-populations-with-rapid-cognitive-decline/423158/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasma-neurodegeneration-and-ad-biomarkers-identify-populations-with-rapid-cognitive-decline/423158.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"Which biomarkers were used to build the rapid cognitive decline risk score?","Question",{"text":113,"@type":114},"The risk score uses four plasma biomarkers: the amyloid-β 42 to amyloid-β 40 ratio, p-tau 181, NFL, and GFAP.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the risk score validated?",{"text":118,"@type":114},"Risk scores developed in the ARIC cohort were applied to participants in the ACHIEVE clinical trial, using the same biomarkers measured on a different platform and assayed with the Alamar CNS protein panel.",{"name":120,"@type":111,"acceptedAnswer":121},"Does adding age and MMSE improve the risk score?",{"text":122,"@type":114},"No. Adding age and Mini Mental State Exam did not improve the predictive performance of the risk scores.",{"name":124,"@type":111,"acceptedAnswer":125},"What is the practical impact of using these plasma biomarker risk scores?",{"text":126,"@type":114},"They can identify subgroups likely to experience rapid cognitive decline and may increase the statistical power of cognitive decline clinical trials.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},423158,1790792430,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":81,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","64 Innovation in Aging, 2025, Vol. 9, No. S2  \ndecline. We used neurodegeneration and AD biomarkers measured in the ARIC cohort (amyloid-β 42 to amyloid-β 40 ratio, p-tau 181, NFL, and GFAP on frozen plasma collected in 2011-13 using the Quanterix SiMoA platform, N = 1825) to develop a risk score for the rate of decline in global cognition factor score and validated its performance among participants of the ACHIEVE clinical trial (same 4 biomarkers assayed using the Alamar CNS protein panel, N = 502 at the 3-year follow-up) . Biomarkers were standardized within platforms using inverse-normal transformation. Cognitive decline risk scores developed in ARIC were applied to ACHIEVE for validation. Biomarker risk scores developed inARIC validated in ACHIEVE with the upper quintile having a mean (95% CI) progression rate of-0.123 (-0 . 137, -0. 108) in ARIC, -0.111 (-0 . 158, -0.065) in ACHIEVE (compared to mean of-0.012 in the total ACHIEVE validation sample). Adding age and Mini Mental State Exam did not improve the risk scores. The power of a clinical trial would change from 5% to 96% as mean annualized cognitive decline increases from-0.012 to-0.111 (selected top risk quintile; a progression SD of 0.25) in a trial of 800 participants and a 20% reduction in cognitive decline from an intervention. In conclusion, risk scores based on plasma biomarkers allow for identification of subgroups likely to experience rapid cognitive decline and may increase the power of cognitive decline clinical trials.  \nAbstract citation ID: igaf122.211  \nPLASMA NEURODEGENERATION AND AD  \nBIOMARKERS IDENTIFY POPULATIONS WITH RAPID  \nCOGNITIVE DECLINE  \nJosef Coresh1, James Pike1, Nicholas Reed2, Priya Palta3, Jennifer Deal4, Kevin Sullivan5, Bharat Thyagarajan6, and Frank Lin4, 1. New York University, New York, New York, United States, 2. New York University Grossman School of Medicine, New York, New York, United States, 3. University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States, 4. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States, 5.  \nUniversity of Mississippi Medical Center-The MIND Center, Jackson, Mississippi, United States, 6. University of Minnesota, Minneapolis, Minnesota, United States  \nPredicting rapid cognitive decline is valuable for patient counseling and targeting clinical trials to slow down this rate of","cbCainP1i8Az7ZrP","https://ap.wps.com/l/cbCainP1i8Az7ZrP","pdf",124909,"English","# Abstract\n## Biomarker-based risk score development (ARIC)\n## Validation in the ACHIEVE clinical trial\n## Model performance and clinical trial power implications","[{\"question\":\"Which biomarkers were used to build the rapid cognitive decline risk score?\",\"answer\":\"The risk score uses four plasma biomarkers: the amyloid-β 42 to amyloid-β 40 ratio, p-tau 181, NFL, and GFAP.\"},{\"question\":\"How was the risk score validated?\",\"answer\":\"Risk scores developed in the ARIC cohort were applied to participants in the ACHIEVE clinical trial, using the same biomarkers measured on a different platform and assayed with the Alamar CNS protein panel.\"},{\"question\":\"Does adding age and MMSE improve the risk score?\",\"answer\":\"No. Adding age and Mini Mental State Exam did not improve the predictive performance of the risk scores.\"},{\"question\":\"What is the practical impact of using these plasma biomarker risk scores?\",\"answer\":\"They can identify subgroups likely to experience rapid cognitive decline and may increase the statistical power of cognitive decline clinical trials.\"}]","Plasma Neurodegeneration and AD Biomarkers Identify Populations With Rapid Cognitive Decline | PDF",1790630358]